Eczema drug study halted early – no results yet
NCT ID NCT06119529
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-stage study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The study was terminated early, so no meaningful results are available. Only 18 participants were planned, and the drug's effects on eczema symptoms were not evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel ACT
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.